Merck & Co has said it will not file its cholesterol drug anacetrapib with regulators, saying that trial results are not good enough for clinical filings. The news came in a brief statement, which ...

It’s the first major partnership for Janux, which was set up in 2017, and could be the last to be organised by Merck’s R&D head Roger Perlmutter who is retiring from the big pharma company at ...

As the Q4 2024 pharma earnings period rolls on through the first month of President Donald Trump’s second term, executives ...

The approvals were based on positive results from EV-302, in which Padcev plus Keytruda resulted in statistically significant ...

Researchers at Penn Medicine conducted a pilot randomized controlled trial to test the hypothesis that an e-triage ...

Chief Financial Officer François-Xavier Roger told reporters. The company is expected to soon face competition from Merck & Co., which is also developing a drug to protect babies against RSV.

Pfizer has announced that its Braftovi (encorafenib) regimen significantly improved both progression-free and overall survival in a late-stage colorectal cancer (CRC) study.

On January 31, Wells Fargo analyst Roger Read downgraded the price target ... FY2024 and expects to return over $10 billion in 2025. Merck & Co., Inc. (NYSE:MRK) is a global healthcare company ...

Pfizer & Astellas’ Padcev plus Keytruda shows long-term efficacy in first-line treatment of locally advanced or metastatic urothelial cancer: New York Wednesday, February 12, 20 ...

Similar to the Democratic senators who have come out forcefully against Kennedy, Cassidy, in an interview with Fox News earlier this month, said that RFK Jr. is “wrong” about vaccines. But he also ...

Senator Roger Marshall and RFK Jr. during a visit in December- courtesy ... including the fees he gets from referring clients in a case against Merck. Kennedy told the committee he's referred hundreds ...